Outcomes by comorbidities with tremelimumab and durvalumab in the phase 3 Himalaya study in unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Rimassa, L.; Dayyani, F.; Kelley, R. K.; Sangro, B.; Chan, S. L.; McCoy, C. L.; Paskow, M. J.; Makowsky, M.; Gupta, C.; Ran, D.; Negro, A.; Abou-Alfa, G. |
| Abstract Title: | Outcomes by comorbidities with tremelimumab and durvalumab in the phase 3 Himalaya study in unresectable hepatocellular carcinoma |
| Meeting Title: | Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2024): The Liver Meeting |
| Journal Title: | Hepatology |
| Volume: | 80 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Nov 15-19 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2024-10-01 |
| Start Page: | S1391 |
| End Page: | S1392 |
| Language: | English |
| ACCESSION: | WOS:001366004003364 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1827 -- Source: Wos |
MSK Authors
-
568Abou-Alfa